Story preview
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
3
in the last 3 days
First reported
2 days ago
2 outlets since
Countries
2 other outlets reported this story in the last 3 days.
Eli Lilly (NYSE: LLY) reported new Phase 2b and Phase 3 data for obesity and diabetes candidates EloraTZP and retatrutide, highlighting weight loss and A1C effects versus existing therapies. EloraTZP, which combines eloralintide with tirzepatide, produced stronger metabolic outcomes in a Phase 2b trial than current…